Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR)

被引：0
作者：
Mélanie Dos Santos
Justine Lequesne
Alexandra Leconte
Stéphane Corbinais
Aurélie Parzy
Jean-Marc Guilloit
Sharmini Varatharajah
Pierre-Emmanuel Brachet
Marine Dorbeau
Dominique Vaur
Louis-Bastien Weiswald
Laurent Poulain
Corentin Le Gallic
Marie Castera-Tellier
Marie-Pierre Galais
Bénédicte Clarisse
机构：
[1] UNICANCER,Clinical Research Department
[2] Centre François Baclesse,Department of Medical Oncology
[3] UNICANCER,Department of Surgery
[4] Centre François Baclesse,Department of Pathology
[5] UNICANCERCentre François Baclesse,Department of Cancer Biology and Genetics
[6] UNICANCERCentre François Baclesse,undefined
[7] UNICANCERCentre François Baclesse,undefined
[8] UNICANCER,undefined
[9] Centre François Baclesse,undefined
[10] Normandie University,undefined
[11] UNICAEN,undefined
[12] ANTICIPE,undefined
[13] ORGAPRED Platform,undefined
来源：
BMC Cancer | / 22卷
关键词：
Gastric cancer; Gastroesophageal junction cancer; Neoadjuvant treatment; Immunotherapy; Spartalizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
    Gubanski, Michael
    Johnsson, Anders
    Fernebro, Eva
    Kadar, Lianna
    Karlberg, Ingegerd
    Flygare, Petra
    Berglund, Ake
    Glimelius, Bengt
    Lind, Pehr A.
    GASTRIC CANCER, 2010, 13 (03) : 155 - 161
  • [42] A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer
    Takaki Yoshikawa
    Akira Tsuburaya
    Ken Shimada
    Atsushi Sato
    Makoto Takahashi
    Wasaburo Koizumi
    Yasuo Yoshizawa
    Kazuhito Nabeshima
    Masayuki Kimura
    Kiyoshi Hataya
    Osamu Kobayashi
    Gastric Cancer, 2009, 12 : 212 - 218
  • [43] A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer
    Yoshikawa, Takaki
    Tsuburaya, Akira
    Shimada, Ken
    Sato, Atsushi
    Takahashi, Makoto
    Koizumi, Wasaburo
    Yoshizawa, Yasuo
    Nabeshima, Kazuhito
    Kimura, Masayuki
    Hataya, Kiyoshi
    Kobayashi, Osamu
    GASTRIC CANCER, 2009, 12 (04) : 212 - 218
  • [44] Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer
    Barone, Carlo
    Basso, Michele
    Schinzari, Giovanni
    Pozzo, Carmelo
    Trigila, Nunziatina
    D'Argento, Ettore
    Quirino, Michela
    Astone, Antonio
    Cassano, Alessandra
    GASTRIC CANCER, 2007, 10 (02) : 104 - 111
  • [45] Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Lordick, F.
    Luber, B.
    Lorenzen, S.
    Hegewisch-Becker, S.
    Folprecht, G.
    Woell, E.
    Decker, T.
    Endlicher, E.
    Roethling, N.
    Schuster, T.
    Keller, G.
    Fend, F.
    Peschel, C.
    BRITISH JOURNAL OF CANCER, 2010, 102 (03) : 500 - 505
  • [46] High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients
    Chen, Yansu
    Xia, Xiaowei
    Wang, Shouyu
    Wu, Xuming
    Zhang, Jianbing
    Zhou, Yan
    Tan, Yongfei
    He, Song
    Qiang, Fulin
    Li, Aiping
    Roe, Oluf Dimitri
    Zhou, Jianwei
    JOURNAL OF GASTROENTEROLOGY, 2013, 48 (09) : 1034 - 1044
  • [47] Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer
    Carlo Barone
    Michele Basso
    Giovanni Schinzari
    Carmelo Pozzo
    Nunziatina Trigila
    Ettore D'Argento
    Michela Quirino
    Antonio Astone
    Alessandra Cassano
    Gastric Cancer, 2007, 10 : 104 - 111
  • [48] Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    F Lordick
    B Luber
    S Lorenzen
    S Hegewisch-Becker
    G Folprecht
    E Wöll
    T Decker
    E Endlicher
    N Röthling
    T Schuster
    G Keller
    F Fend
    C Peschel
    British Journal of Cancer, 2010, 102 : 500 - 505
  • [49] Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma
    Lee, J.
    Kang, W. K.
    Kwon, J. M.
    Oh, S. Y.
    Lee, H. R.
    Kim, H. J.
    Park, B. B.
    Lim, H. Y.
    Han, M. J.
    Park, J. O.
    Park, Y. S.
    ANNALS OF ONCOLOGY, 2007, 18 (01) : 88 - 92
  • [50] Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort
    Simon Pernot
    Emmanuel Mitry
    Emmanuelle Samalin
    Laetitia Dahan
    Cécile Dalban
    Marc Ychou
    Jean-François Seitz
    Hajer Turki
    Thibault Mazard
    Aziz Zaanan
    Céline Lepère
    Jean-Nicolas Vaillant
    Bruno Landi
    Philippe Rougier
    Julien Taieb
    Gastric Cancer, 2014, 17 : 341 - 347
12345